AVITA Medical, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AVITA Medical, Inc. (Nasdaq: RCEL) on January 13, 2026. The filing reports the entry into a new material definitive credit agreement and the simultaneous termination of a prior credit facility. The company is a Delaware corporation headquartered in Valencia, California.
Key Financial Metrics and Capital Structure
- New Debt Facility: Entered into a five-year senior secured credit facility with an aggregate principal amount of up to $60 million.
- Initial Funding: $50 million was funded on the closing date (January 13, 2026).
- Additional Commitment: An additional $10 million is available at the company's discretion by March 31, 2027, subject to a net revenue requirement.
- Interest Rate: Cash interest accrues at the greater of the SOFR rate or 4.00%, plus a 7.50% margin. A default rate applies an additional 4.00% penalty.
- Liquidity Covenant: The company must maintain at least $5 million of unrestricted cash at all times.
- Refinancing: The new facility was used to repay in full and terminate the existing credit agreement dated October 18, 2023.
Material Changes and Equity Issuance
The company executed a refinancing transaction, replacing its prior debt obligations with the new Perceptive Credit Holdings V, LP facility. Concurrently, the company issued a warrant certificate (the "Warrant") to the lender, subject to shareholder approval under Australian Securities Exchange rules.
- Warrant Terms: Covers up to 500,000 shares of common stock, with an additional 150,000 shares vesting if the additional $10 million commitment is drawn.
- Exercise Price: The lower of the 10-day VWAP prior to the closing date or the 10-day VWAP prior to the warrant issuance date.
- Term: 10 years from the issuance date.
- Exit Fee: A 5% exit fee on the aggregate principal amount is triggered if shareholder approval for the warrant is not secured by September 30, 2026.
Guidance, Risks, and Covenants
The filing references a press release (Exhibit 99.1) containing updated revenue guidance for the fourth quarter and full year 2025, as well as 2026 revenue guidance; however, the specific numerical values for this guidance are not detailed within the text of this 8-K.
Key Risks and Covenants:
- Events of Default: Include failure to obtain warrant shareholder approval by November 30, 2026, nonpayment, insolvency, and material adverse effects.
- Financial Maintenance: The company must maintain a specified minimum net revenue for each trailing twelve-month period ending on the last day of a fiscal quarter.
- Restrictive Covenants: Limitations on incurring additional indebtedness, creating liens, making acquisitions, paying dividends, and engaging in affiliate transactions.
- Prepayment Premium: Ranges from 1% to 10% of the prepaid amount.
Investor Verification Checklist
- Verify the specific 2025 and 2026 revenue guidance figures in the press release attached as Exhibit 99.1.
- Confirm the status of the Australian Securities Exchange shareholder approval required for the warrant issuance by the September 30, 2026 deadline.
- Review the exact "specified minimum net revenue" threshold required under the financial maintenance covenant in the full Credit Agreement (Exhibit 10.1).
- Assess the impact of the 7.50% interest margin and potential prepayment premiums on future cash flow.
- Monitor the company's ability to maintain the $5 million unrestricted cash covenant.